Company News: Page (1) of 1 - 12/07/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook

Asia-Pacific Asthma Therapeutics Markets 2017-2023 - Promising Product Pipeline and Launch of First-in-Class Molecules

(December 07, 2017)

Dublin, Dec. 07, 2017 (GLOBE NEWSWIRE) -- The "Asthma Therapeutics in Asia-Pacific Markets to 2023 - High Prevalence and Highly Priced Existing & Upcoming Biologics will Drive the Market" report has been added to Research and Markets' offering.



The report "Asthma Therapeutics in Asia-Pacific Markets to 2023 High Prevalence and Highly Priced Existing & Upcoming Biologics will Drive the Market" provides an introduction to asthma, detailing the epidemiology, etiology, diagnostic techniques, pathophysiology and prognosis for patients. An analysis of current treatment algorithms and options is also included.

Asia-Pacific asthma therapeutics market is forecast to grow significantly over the forecast period, from $4.1 billion in 2016 to a projected value of $6 billion by 2023, at a compound annual growth rate (CAGR) of 5.4%.

Asthma treatment can be classed as either long-term control medication, aimed at controlling persistent asthma, or quick-relief medication, for the relief of exacerbations and acute symptoms. Long-term control medication includes inhaled corticosteroids (ICS), immunomodulators, leukotriene modifiers, cromolyn sodium, nedocromil and methylxanthines. In addition, long-acting beta-adrenoceptor agonists (LABA) can be used in combination with ICSs but not as monotherapies for moderate or severe persistent asthma. Currently, only two biologics Xolair (omalizumab) and Nucala (mepolizumab) are approved as add-on therapy for the treatment of allergic and severe refractory eosinophilic asthma in the Asia-Pacific region.

Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   USDailyNews ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

Our Privacy Policy --- @ Copyright, 2017 Digital Media Online, All Rights Reserved